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Abstract This paper summarises the ﬁve presentations at
the First International Workshop on Systems Radiation
Biology that were concerned with mechanistic models for
carcinogenesis. The mathematical description of various
hypotheses about the carcinogenic process, and its com-
parison with available data is an example of systems
biology. It promises better understanding of effects at
the whole body level based on properties of cells and
signalling mechanisms between them. Of these ﬁve
presentations, three dealt with multistage carcinogenesis
within the framework of stochastic multistage clonal
expansion models, another presented a deterministic
multistage model incorporating chromosomal aberrations
and neoplastic transformation, and the last presented a
model of DNA double-strand break repair pathways for
second breast cancers following radiation therapy.
Introduction
Five presentations at the First International Workshop on
Systems Radiation Biology held at GSF on 14–16 February
2007 were concerned with mechanistic models for radia-
tion carcinogenesis. These presentations are summarized in
this manuscript. Of these ﬁve presentations, three (given by
Heidenreich, Little, and Moolgavkar) dealt with the theme
of multistage carcinogenesis within the framework of
stochastic multistage clonal expansion models. The pre-
sentation by Scho ¨llnberger discussed a deterministic
multistage model incorporating chromosomal aberrations
and neoplastic transformation. Finally, Thomas presented a
model of DNA double-strand break (DSB) repair pathways
for second breast cancers following radiation therapy.
Stochastic multistage clonal expansion models
for carcinogenesis
Stochastic multistage clonal expansion models are exten-
sions of the two-stage clonal expansion (TSCE) model of
carcinogenesis generally attributed to Moolgavkar and
Venzon [1] and Moolgavkar and Knudson [2] and some-
times referred to as the MVK model. In this, its simplest,
incarnation, the model assumes that initiated cells, the
hallmark of which is a slight growth advantage over normal
neighbours, arise from stem cells according to a non-
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undergo a stochastic birth–death–mutation process with the
birth and death process giving rise to clones of initiated
cells and the mutation process leading to the conversion of
an initiated cell into a fully malignant cell. Multistage
extensions of this basic model have been proposed by
various investigators. A couple of these extensions are
discussed later in this report. The introduction of one or
more stages with stochastic clonal expansion in multistage
cancer models has profound implications for inferences
drawn from the models.
Clonal expansion and carcinogenesis (Moolgavkar)
Clonally expanding cell populations are important in car-
cinogenesis and modelling their dynamics stochastically
rather than deterministically has interesting consequences.
We give some examples here.
Gestational mutations and cancer
Frank and Nowak [3] suggested that mutations at critical
loci during the exponential phase of growth during gesta-
tion could have important implications not only for
childhood, but also for adult cancers. Mutations occurring
early in gestation would give rise to jackpots (i.e. clones) of
cells with mutations at critical loci increasing the proba-
bility of cancer in an individual carrying these mutations.
The quantitative consequences of gestational mutations
were investigated by Meza et al. [4]. They used the Luria–
Delbruck model for jackpots in tandem with the Luebeck–
Moolgavkar model [5] for colon cancer and concluded that,
depending on the rates of gestational mutations, between 2
and 20% of colon cancers in the surveillance epidemiology
and end results (SEER) registry in the year 2000 arose from
stem cells that had sustained one or more critical mutations
during gestation. Meza et al. [4] also investigated the
cancer risks associated with radiation exposure during
gestation and concluded that radiation during the last tri-
mester of pregnancy carried the highest risk, consistent
with the epidemiological data.
Clonal expansion and cancer incidence rates
Stochastic clonal expansion of intermediate cells on the
pathway to cancer also has important implications for the
incidence of cancer in human populations. Some of these
ﬂow from the fact that stochasticity of carcinogenesis
introduces heterogeneity of cancer risk. Even if one starts
off with a completely homogeneous population, with the
passage of time, the population becomes increasingly het-
erogeneous with respect to cancer risk as a consequence of
the stochasticity of the carcinogenic process. Much of this
heterogeneity arises from the fact that clonal expansion of
intermediate cells is modelled by stochastic birth and death
processes, leading to distributions of cells in intermediate
stages on the pathway to carcinogenesis. Unfortunate
individuals in the upper tails of these distributions tend to
develop cancer earlier than their more fortunate brethren
who lie in the lower tails. An immediate consequence of
heterogeneity is the widely observed departure of cancer
incidence rates below the log–log incidence predicted by
deterministic versions of many multistage models.
Heterogeneity of intermediate cell populations also
plays an important role in the temporal evolution of
cancer risk in a population exposed to a carcinogen, such
as ionising radiation or cigarette smoke. When smokers
quit, the incidence rates of lung cancer fall below those
among continuing smokers and gradually over a period of
15–20 years approach those among life-long non-smokers.
While this decline to background rates has often been
attributed to repair of smoke-induced damage of lung
tissue, it can be explained by the heterogeneity in the
population of intermediate cells among smokers. Within
the framework of the TSCE model, the main effect of
tobacco smoke is to stimulate clonal expansion of initiated
cells (promotion). This leads to a distribution of initiated
cells that is shifted to the right, i.e., to larger numbers, but
overlaps the distribution of initiated cells among non-
smokers. When smokers quit, individuals in the upper tail
of the distribution develop lung cancer at a higher rate
than the non-smokers. Eventually, however, the high-risk
individuals are depleted, and the risk among ex-smokers is
now determined by individuals in the lower tail of the
distribution, which overlaps the distribution among non-
smokers.
The so-called inverse exposure-rate effect for high-LET
radiation has also been explained in terms of a promotional
effect of high-LET radiation in carcinogenesis, ﬁrst pos-
tulated as a result of an analysis of the Colorado Plateau
miners’ data [6] and subsequently conﬁrmed by analysis of
experimental data [7]. More recently, it has been suggested
that low-LET radiation may also have some promoting
activity [8]. The promoting action of radiation is discussed
in more detail (section of Heidenreich) later in this paper.
With an inverse exposure-rate effect, protraction of the
time over which a given exposure is administered has an
interesting consequence, namely, one observes crossing
incidence functions, a phenomenon that is difﬁcult to
detect and address using conventional epidemiological
methods. Methods of analyses based on ideas of multistage
carcinogenesis are much better suited to addressing issues
of this type.
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The stochastic treatment of clonal expansion allows also
for the development of expressions for the distributions of
numbers and sizes of pre-malignant lesions, such as
altered foci arising in rodent hepatocarcinogenesis
experiments, and adenomatous polyps in the human colon
[9, 10], which can then be used for data analyses [11, 12].
Jeon et al. [10] developed expressions for the distribution
of the number and sizes of adenomatous polyps based on
the Luebeck–Moolgavkar model using a combination of
simulation and mathematical techniques. They used these
expressions to devise optimal screening schedules for
colon cancer [10].
Epidemiological data and models of radiation
carcinogenesis (Heidenreich)
Unfortunately, cancer biologists have not yet worked out
the details of how cancer evolves in an organ [13].
Therefore, fairly crude simpliﬁcations of these processes
have to be used when trying to connect the most relevant
biological processes with the observed risk patterns due to
ageing or radiation. When extracting information about the
cancer process, or the action of radiation from epidemio-
logical or experimental cancer incidence data, it is crucial:
• To understand what quantities are identiﬁable in the
models. Ideally, the signals to look for are selected
before any analysis is done
• To choose the best available data (power, quality) for
the addressed question
• Alternatively, at least to verify that the tested models
make different predictions for the chosen data.
This type of research requires cooperation of epidemiol-
ogists, biologists and modellers (usually physicists or
mathematicians). Depending on the deﬁnition, it may thus
be considered as systems radiation biology.
Here solid cancers are considered, and the action of
radiation is studied. To be speciﬁc, the following model-
components are used:
Initiation: A Poisson process resulting in cells with a
growth advantage
Promotion: Slow clonal expansion of initiated cells
Conversion: A rate-limiting step from initiated cells to
malignant ones
Lag time: Deterministic growth of one malignant cell to
an observed tumour.
Each of these components could be radiation-dependent
and could consist of sub-steps.
Radiation action on initiation
According to a conventional view, radiation only inﬂu-
ences the initiating event of the multi-step carcinogenic
process [14]. With this assumption, 50 mGy gamma-rays
were estimated to be about as efﬁcient in initiation as
1 year of normal life [15, 16]. If part of the effects in the
atomic bomb survivors data is due to other radiation
actions, than this number may become larger [17]. In the
lung cancer induction of mice, a dose rate of about
10 mGy/day was estimated to double the spontaneous
initiation rate [18]. High LET radiation was also found to
be acting on initiation [19, 20].
Radiation action on promotion
Radiation effects on the effective clonal expansion rate of
initiated cells (promotion) have been found for radon and
lung cancer [19–21], alpha-particles from Thorotrast in
liver [22], alpha-particles from radium in bone cancer [23],
as well as for neutrons and gamma-rays on lung cancer in
mice [18].
The most direct evidence for a promoting action of
radiation comes from protraction effects. As long as effects
are ignored that are typically observable only in old age,
the following holds:
Initiating action is additive: two exposures with a
sufﬁcient time between them give (approximately) an
excess risk, which is the sum of the single exposure
excess risks.
Promoting action is multiplicative: two exposures with a
sufﬁcient time between them give (approximately) a
relative risk, which is the product of the single exposure
relative risks.
Fractionated exposure with equal fractions may be best
to test between these possibilities, as there is no freedom
due to varying dose rate.
At Paciﬁc North–West National Laboratory (PNNL),
rats were exposed for 2–700 days at constant exposure rate.
The excess relative risk (ERR) per 100 working-level
months (WLM) radon for fatal lung tumours based on the
ﬁtted background was estimated [24] (see Fig. 1). Initiation
only predicts a decrease of ERR/WLM with duration, due
to age-at-exposure effects.
The radiation action that induces promotion is not clear.
At least one mechanism was proposed [25]. If (spontane-
ously) initiated cells can replace neighbouring cells killed
by radiation faster than normal cells, then there is a pro-
moting effect of radiation.
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If conversion is radiation-sensitive, then an acute irradia-
tion induces a peak in risk after the lag time. This may be
smeared out if the assumed deterministic growth of
malignant cells is distributed over a period of time.
In the JANUS experiment, a large number of mice were
exposed to acute gamma-rays and neutrons up to high doses
[18]. The lung cancer cases are plotted in Fig. 2. There is
not a single lung cancer case up to 400 days after exposure.
The lag time should deﬁnitely be shorter than this.
In various other analyses, the radiation-induced con-
version rate relative to the baseline one was found to be a
factor of at least ten smaller than that for initiation [21, 24].
This agrees qualitatively with radio-biological under-
standing: candidate mutations for late events may be
mostly induced spontaneously.
Radiation action on lag time
In neutron-exposed mice, the estimated lag time to lung
cancer was found to be signiﬁcantly smaller than in
gamma-exposed mice [18]. Possibly neutron-induced
instability gives more aggressive cancer-subtypes than
occur spontaneously or after gamma-ray exposures.
Distribution of risk due to the stochastic cancer process
The considered cancer model is a stochastic one. The
mathematical description does not use the expectation of
the number of initiated cells, but their distribution. As the
number of initiated cells is proportional to the risk after the
lag time, this allows one to calculate a distribution of risk at
any given age. Under the assumptions of the present clonal
expansion model it was found that:
The estimated baseline risk for liver cancer of more than
95% of a population at age 40 is less then 10% of the
population risk, while it is more than 10-fold for the top
percentile in risk [26].
After the injection of Thorotrast, the estimated relative
risk for the low baseline risk person is more than 10
times larger than for the top percentile in baseline risk
[27]. For the high baseline risk group, cancer is not a rare
disease. Therefore, the population-based estimate of
relative risks can be an underestimation for most persons
most of the time.
A (thorny) path to better risk estimates at low doses
Integrated projects such as the EU-project RISC-RAD [28]
should demonstrate that productive interactions between
cancer modelling and radio-biology are possible. This may
help in going from a more detailed understanding of radi-
ation actions observed in experimental work to quantitative
risk estimates. This in turn may be the only way to improve
the estimates of small risks after radiation beyond direct
epidemiology.
Multistage models for cancer incorporating genomic
instability (Little)
There are many biological data suggesting that the initi-
ating lesion in the multistage process leading to cancer
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Fig. 1 Estimate of the lifetime excess relative risk per nominal
exposure unit of rats exposed to radon for various periods of time with
a constant exposure rate (100 WL). The dashed line represents model
estimates with only an initiating radiation action (I-model), and the
solid line one with initiation and promotion (IP-model) (based on
model ﬁts carried out by Heidenreich et al. [24])
Fig. 2 Number of lung cancer cases in mice after acute exposure to
gamma-rays and neutrons (based on model ﬁts carried out by
Heidenreich et al. [18])
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123might be one involving a destabilization of the genome
resulting in elevation of mutation rates, reviewed by
Morgan [29, 30]. Loeb [31, 32] has presented evidence that
an early step in carcinogenesis is mutation in a gene con-
trolling genome stability. Stoler et al. [33] showed that
there are 11,000 mutations per carcinoma cell for a number
of different cancer types, again implying that genomic
destabilization is an early event in carcinogenesis. In par-
ticular, there is strong evidence of such an early genomic
destabilization event for colon cancer [31–33]. However,
the question of whether chromosomal instability is the
initiating event in carcinogenesis, in particular colon can-
cer, is controversial. Tomlinson and Bodmer [34] argue
that cancer is an evolutionary process, and that the
observed accumulation of chromosomal and other damage
in colon cancers may simply be the result of selection for
cells with growth advantage.
Recently, two papers have appeared proposing formu-
lations of stochastic carcinogenesis models that
incorporate genomic instability (GI) [35, 36], both applied
to colon cancer. In contrast, Luebeck and Moolgavkar [5]
have recently proposed a four-stage stochastic model
positing inactivation of the adenomatous polyposis coli
(APC) gene followed by a high frequency event, possibly
positional in nature, an extension of the two-stage clonal
expansion model of Moolgavkar and Venzon [1] and
Knudson [37] (the so-called MVK model); this model does
not assume GI. The paper of Little and Wright [36] pro-
posed a general class of carcinogenesis models that
includes, as special cases, the models proposed by Lue-
beck and Moolgavkar [5] and Nowak et al. [35], illustrated
in Fig. 3. The model of Little and Wright [36] also gen-
eralizes the class of so-called generalized MVK models
developed by Little [38], and which in turn therefore
generalizes the two-mutation model of Moolgavkar and
Venzon [1] and Knudson [37]. The model is close in spirit
to the model of Mao et al. [39].
Little and Li [40] have recently compared the goodness
of ﬁt to US SEER [41] colon cancer data of three models
developed by Little and Wright [36] with the ones recently
proposed by Nowak et al. [35] and Luebeck and Mool-
gavkar [5]. The best ﬁtting models were the two-stage
model of Nowak et al. [35] and the two-stage model of
Little and Wright [36], with the four stage model of Lue-
beck and Moolgavkar [5] not markedly inferior; model ﬁts
are illustrated in Fig. 4 (taken from Little and Li [40]). The
ﬁts of the three-stage and ﬁve-stage models were somewhat
worse (P\0.05), the ﬁve-stage model ﬁtting particularly
poorly (P\0.01). Both optimal genomic instability mod-
els predicted cellular mutation rates that are at least 10,000
times higher after genomic destabilization, for both sexes
[40]. These large elevations in mutation frequency are not
inconsistent with a variety of biological data [31, 40, 42–
44]. In particular, Loeb and colleagues [31, 42] derive
estimates of numbers of gross chromosomal abnormalities
in human tumours, which are of the order of 10,000–
100,000-fold elevated compared with normal tissue.
Mutation rates 1,000–100,000-fold elevated have been
observed in bacteria with defects in the dnaQ (DNA
polymerase coding) gene [43, 44].
The work of Little and Li [40] suggests that analyses of
data that contain information only in relation to the age
distribution of cancer does not possess the power to dis-
criminate between models and hence to conﬁrm or to
falsify the hypothesized involvement of GI in colon cancer.
It is possible that additional analysis, incorporating, for
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123example, quantitative information on exposure to various
mutagenic agents (e.g. ionising radiation) would have the
power to discriminate between these models.
State-Vector Model for in vitro neoplastic
transformation (Scho ¨llnberger)
The State-Vector Model is a deterministic multistage
model for in vitro neoplastic transformation and was
tested on data that show a U-shaped dose–response curve
at low doses of c-radiation [45]. In the model, initiation
results from DSBs induced by radiation and endogenous
processes. Promotion results from a disruption of inter-
cellular communication and a compensatory proliferation
of initiated cells [46]. Cell death is allowed via radiation-
induced necrosis and also at low doses via bystander-
induced apoptosis. This pathway has been hypothesized
[47] to be responsible for the observed decrease of the in
vitro neoplastic transformation frequency below the
spontaneous level [45, 48, 49]. The protective apoptosis-
mediated bystander effect is implemented via rate con-
stant kap. At ﬁrst, the model with kap = 0 is ﬁtted to the
control and high dose data points for immediate and
delayed plating. The model with kap as the only free
parameter was then ﬁtted to the whole data set, with the
other parameter values as ﬁxed inputs [50, 51]. Figure 5
shows the data of Redpath et al. [45] and the different
model contributions. Since the publication of these studies
[50, 51], 95% conﬁdence intervals (CI) were calculated
for the best-estimated values using the residuals and the
Jacobi matrix obtained in local model ﬁts that follow the
global search of the parameter space. For delayed plating,
the best estimated value for kap is 0.054/day [51] (95%
CI: 0.031–0.078) and for immediate plating kap = 0.022/
day (95% CI: 0.007–0.036).
The relevance of in vitro neoplastic transformation for
cancer induction in humans has caused discussion [45].
Cells transformed in vitro cause sarcoma after inoculation
into host animals [52]. The relative risks calculated from
human and mouse in vitro data [45, 48, 49] are remarkably
similar to those from human epidemiological studies, par-
ticularly for breast cancer and leukaemia [45]. Mitchel
(personal communication) points out the importance of in
vitro neoplastic transformation and argues that if a cell in
vivo is ‘‘near transformation’’ for whatever reason and
would eventually develop into a cancer, and if radiation
protects against and slows/reverses that process as dem-
onstrated [53–58], then this would be critically important.
Protective mechanisms such as homologous recombination
(HR), an error-free DSB repair mechanism that could prove
to be crucially important in the observed reduction of the
neoplastic transformation frequency below the spontaneous
level, are evolutionarily conserved [59]. The conservation
of HR reaches from prokaryotes to lower and higher
eukaryotes including humans [57] and neoplastic trans-
formation of human and other mammalian cells facilitates
the study of such mechanisms.
Modelling DNA double-strand break repair pathways
for second breast cancers following radiotherapy
(Thomas)
Ataxia–telengiactasia (A–T) is a rare recessive disorder
caused by homozygous truncating mutations in ataxia-
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123telangiectasia mutated gene (ATM), with one of its features
being extreme radiation sensitivity. It has been hypothe-
sized that ATM heterozygotes have increased risk of
cancer, particularly breast [60, 61] and that this suscepti-
bility interacts with ionising radiation exposure [62]. Gatti
et al. [63] suggested that the increased cancer risk is
associated with missense mutations rather than the trun-
cating mutations that cause A–T. In any event, it is well
established that ATM plays a central role in two pathways
for repair of DSBs, the HR repair and the nonhomologous
end-joining repair pathways.
The Women’s Environment, Cancer, and Radiation
Epidemiology (WECARE) study was established to test the
hypothesis that women who are carriers of a mutant allele
in the ATM or BRCA1/2 genes (or other DNA repair genes)
are more susceptible to a second radiation-induced breast
cancer than are non-carriers. A population-based, nested
case–control study was conducted in a cohort of ﬁrst breast
cancer patients from ﬁve centres in the US and Denmark. A
total of 708 cases of bilateral breast cancer were identiﬁed
and individually matched on centre, age at and time since
ﬁrst cancer to 1,397 controls with unilateral breast cancer.
Controls were also counter-matched 2:1 on whether or not
they received radiotherapy as recorded in the cancer reg-
istries and doses to each of eight locations in the
contralateral breast (the one at risk of a second cancer)
were estimated by phantom dosimetry. The design and
analysis of this study is fully described in Bernstein et al.
[64]. All subjects were genotyped for ATM, BRCA1 and
BRCA2, using a staged approach consisting of DHPLC
followed by direct sequencing [65]. Mutation detection in
other DNA repair genes is currently underway.
Wehavedevelopedahierarchicalmodellingstrategy[66]
to analyse the effects of the numerous rare variants in ATM,
as well as to develop a comprehensive model for all these
genes and six others currently being tested. The ﬁrst level of
themodelisastandardconditionallogisticregressionmodel
of the form logit Pr(Yi =1 )=a + RjbjXij + c Zi where
Yi denotes disease status for subject i, Xij is an indicator for
variant j, and Zi is a vector of ﬁxed covariates (including the
offset term needed to allow for the countermatching). In the
second level, the log relative risk coefﬁcients (bj) are in turn
regressed on a vector of ‘‘prior covariates’’ Wj describing
characteristics of the variants, such as indicators for type of
variant, SIFT score, etc. Preliminary analyses found no
signiﬁcant effects of any of these prior covariates, but the
risk estimates for individual variants were considerably
stabilized by the second-level model, particularly for the
rarer variants.
We are currently conducting a series of functional
assays on cell lines from a random sample of ﬁve subjects
with each of the ten most common variants and all indi-
viduals with rare variants. Each cell line will be assayed
(with two replicates each) for ATM expression levels, ATM
kinase activity, cell cycle checkpoint activation, and colony
survival after ionising radiation exposure. These assays can
then be used in the hierarchical modelling strategy to
improve the prediction of the effects of individual variants
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Fig. 5 Transformation frequency for CGL1 cells irradiated with c-
radiation [45]. Error bars represent 95% CI. a Data for immediate
plating and SVM ﬁt showing the three different contributions (dash
line direct, dotted line bystander, solid line total). The direct
contribution relates to a model ﬁt with kap = 0 to control and high
dose data for delayed and immediate plating [51]. The contribution of
the bystanders was calculated as the difference between the direct and
the total contribution. b Data for delayed plating and SVM ﬁt showing
the three different contributions (dash line direct, dotted line
bystander, solid line total). For the SVM ﬁts denoted as ‘‘total’’, the
95% CI are shown for the low doses (dash–dot). Insets low-dose
range with the x-axis units in Gy (reproduced from Scho ¨llnberger
et al. [51])
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of variants with similar functional characteristics.
We are also currently genotyping six other genes
involved in DSB repair (CHEK2, TP53BP1, MDC1,
MRE11, RAD50 and NBS1) and will expand our hierar-
chical model to include these genes and their interactions
with each other and with radiation dose. We are also
hoping to carry out a genome-wide association scan as
well. In this way, we aim to build a comprehensive model
for DNA damage from ionising radiation and competency
of the various repair pathways.
Conclusion
Systems biology promises better understanding of cancer
induction through understanding and modelling properties
of cells, and the signalling mechanisms between them. The
works presented here demonstrate different approaches of
dealing with this issue.
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